|
Fibrosis Research
2005
Page One:
Daily cannabis smoking as a
risk factor for progression of fibrosis in chronic hepatitis C
July 19, 2005
Etanercept Treatment to Slow
Fibrosis Progression Shows No Histological or Biochemical Improvement in
Chronic HCV Genotype 1 Nonresponders to Peginterferon/Ribavirin
June 09 2005
Simple Fibrosis Tests May Render Liver Biopsy Unnecessary Only in a Minority
of Patients with Chronic HCV
June 09 2005
Long-term Fibrosis Progression in Nonresponders to Interferon-based Therapy
May 30 2005
Baseline Fibrosis Score Does Not Predict SVR to Peginterferon Alfa-2a (Pegasys)
Plus Ribavirin in HCV Patients with Persistently ˇ°Normalˇ± ALT Levels
May 19 2005
Role Of CYP2D6 Polymorphism in Predicting Liver Fibrosis Progression Rate
in Caucasian Patients With Chronic Hepatitis C
May 19 2005
Page Two:
Fibrosis Evaluation: Comparison of FibroScan with Liver Biopsy, Fibrotest,
Fornscore, Apri, Hyaluronan, Prothrombin Time, and AST/ALT Ratio
May 03 2005
Screening for Fibrosis with Non-invasive Biomarkers (Fibrotest) in
Hyperlipidemic Patients
May 02 2005
Are Current Fibrosis Serum Markers an Adequate Alternative to Liver Biopsy?
May 02 2005
MONITORING LIVER ELASTICITY: A NEW TOOL TO MEASURE LIVER FIBROSIS
DURING THERAPY
April 17 2005
Interferon's Benefits for Fibrosis Studied
Mar 16 2005
Relationship Between Serum Ferritin, Hepatic Iron Staining, Diabetes
Mellitus and Fibrosis Progression in Patients with Chronic Hepatitis
Mar 10 2005
Predicting Progressive Fibrosis Stage by Baseline and Subsequent Liver
Biopsy
Mar 03 2005
Impact of Steatosis on the Progression of Fibrosis in Patients with Mild
Hepatitis
Jan 06 2005
Women May be Protected Against Fibrosis, Suggests Study
2004
Page Three:
Pegasys/RBV Improves Fibrosis in Responders, relapsers
& Nonresponders with Advanced Fibrosis
Dec 06 2004
Page Four:
Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for the Treatment of
Chronic HCV and Compensated Cirrhosis/Fibrosis
11-10-2004
Serum caspase activity and liver fibrosis in patients with hepatitis C
11- 08- 2004
AASLD: Smoking Marijuana Raises Fibrosis Risk in
Patients With Chronic Hepatitis C Infection
Daily smoking of cannabis—but not tobacco—associated with more rapid
fibrosis in HCV patients
11-02-2004
Page Five
Progression of hepatic fibrosis in patients with hepatitis C: a prospective
repeat liver biopsy study; 33% showed progression of at least 1 fibrosis
point
10-04-04
Long-Term
Outcomes in HCV with SVR: cure, regression of fibrosis
Fatty
Liver Accelerates Fibrosis: diabetes, mitochondrial dyfunction, obesity
associated
10-01-04
Impact of competing risks on observed rate of
hepatitis C progression
09-24-2004
Natural history of initially mild chronic hepatitis C
Studies on the natural history of initially mild chronic disease
indicate that the short-term outcome is always benign. However, progression
of liver fibrosis can be observed at long-term (>5–7 years) follow-up,
particularly in those cases who have elevated and/or fluctuating
transaminase levels.
08/25/2004
Serum
Immunoglobulins Predict the Extent of Hepatic Fibrosis in HCV Patients
08/11/2004
Common
Heterozygous Hemochromatosis Gene Mutations Are Risk Factors for
Inflammation and Fibrosis in Chronic Hepatitis C
08 /11 /2004
Intercept Pharmaceuticals Announces Publication of
Study Demonstrating Its Lead Compound Can Reverse Liver Fibrosis
08 /11/ 2004
Hepatic
Fibrosis Influences Early Virological Response Rates in
Chronic Hepatitis C
06/16/04
iscum
Album and Solanum Lycopersicum Inhibit Fibrosis in Chronic Hepatitis C
05/24/04
Treatment
with Peginterferon Alfa-2b (PEG-Intron) Plus Ribavirin Is Cost-effective for
Hepatitis C Patients with F1 Fibrosis
05/24/04
Update on Cirrhosis -- The Role of Fibrosis
Markers
05/19/2004
Fibrosis
Progression Is Dependent upon Hepatic Inflammation in Chronic Hepatitis C
05-26-04
Factors
Associated with HCV Stage 3/4 Fibrosis
05-26-04
Page Six:
2004
March - April 2004
The Severity of Liver Fibrosis Is Associated with High Leptin Levels in
Chronic Hepatitis C
|
